Alzheimer markers assays

Alzheimer markers assays

The Lumipulse G pTau 181 and β-Amyloid 1-40 assays are the latest additions to Fujirebio’s fully automated Neuro product line and complement the previously launched Lumipulse G Total Tau and β-Amyloid...

Supplied by Fujirebio Europe N.V.


The Lumipulse G pTau 181 and β-Amyloid 1-40 assays are the latest additions to Fujirebio’s fully automated Neuro product line and complement the previously launched Lumipulse G Total Tau and β-Amyloid 1-42 assays. These assays are intended to measure β-Amyloid1-42, β-Amyloid1-40, total Tau and pTau181 in cerebrospinal fluid (CSF). Altogether, these four CSF markers support the diagnosis of Alzheimer’s disease, with the β-Amyloid1-42 / β-Amyloid1-40 ratio additionally being able to reduce the effect of inappropriate pre-analytics. These four assays are now available and can be run on the LUMIPULSE G600II and G1200 instruments. In comparison to the company’s INNOTEST predecessor assays, these newly CE-marked Lumipulse assays use the same well-established antibodies and show an improved performance. Low volume tests, like CSF biomarker analyses, generally benefit from the Lumipulse cartridge principle where one sample equals one test (per analyte), avoids wastage of reagents and the need for batch-testing.


Contact form

Get in touch directly with the above supplier

Your email address will not be communicated to any third party other than the above supplier for the purpose of fulfilling this enquiry. For more information: read our privacy policy.